首页> 外文期刊>Primary health care research & development >Individualisation or standardisation:trends in National Health Service prescription durations in England 1998-2009
【24h】

Individualisation or standardisation:trends in National Health Service prescription durations in England 1998-2009

机译:个性化或标准化:1998-2009年英格兰国家卫生服务部门处方时间的发展趋势

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Aim: This study aims to evaluate changes in the durations of English National Health Service prescriptions, as indicated by the volumes of unit doses supplied between 1998 and 2009, and consider relevant policy implications. Background: Around the world, countries are seeking to manage the increase in medicines prescribing. In England, many primary care organisations, using limited supporting evidence of cost-effectiveness and clinical improvement, have sought to restrict the number of dosage units on a prescription to 28 days supply. This is based on a conviction that this reduces wastage costs. Methods: Prescription Cost Analysis (PCA) statistics for England for the period January 1998 to December 2009 were used to analyse trends in the average number of unit doses (tablets or capsules) supplied per prescription for 11 drugs supplied in 34 different presentations. Findings: The changes in prescription lengths observed between 1999 and 2009 ranged from 14.2% in the case of Amoxicillin 500 mg capsules to 241.3% in the case of Levothyroxine 50mg tablets. All but four of the medicines selected showed statistically significant negative correlations (r.0.8, P, 0.001) between the year of prescribing and the prescription length. If prescription lengths had been the same in 2009 as they were in 1999, then 33 million fewer prescription items would have been written for the preparations in this analysis. This shift across a range of medications suggests a generalised change in prescribing behaviour. The full balance of benefits and costs associated with this trend, as expressed via drug wastage avoided, patient (in)con-venience experienced, professional time costs incurred or saved and positive or negative health outcome impacts, is not known. Although this study does not provide a definitive answer favouring prescription duration individualisation as opposed to standardisation, the available evidence indicates that policies that rigidly favour 28-day standard periods may require review.
机译:目的:本研究旨在评估1998年至2009年间提供的单位剂量数量所指示的英格兰国家卫生服务部门处方时长的变化,并考虑相关的政策含义。背景:在世界范围内,许多国家都在设法控制药品处方的增加。在英格兰,许多初级保健组织使用有限的成本效益和临床改善证据来寻求将处方药的剂量单位数限制为28天。这是基于这样的信念,即可以减少浪费成本。方法:使用英格兰1998年1月至2009年12月的处方成本分析(PCA)统计数据,分析了针对34种不同表现形式提供的11种药物的每张处方提供的平均单位剂量(片剂或胶囊剂)的趋势。结果:1999年至2009年期间观察到的处方时长变化范围为:阿莫西林500 mg胶囊为14.2%,左旋甲状腺素50mg片剂为241.3%。除四种药物外,所有其他药物在处方年份和处方时长之间均显示出统计学显着的负相关性(r.0.8,P,0.001)。如果2009年的处方时长与1999年的时长相同,则本次分析中准备的处方项目将减少3300万份。一系列药物的转移表明处方行为的普遍变化。尚不知道与这种趋势相关的收益和成本的全部平衡,例如避免使用药物浪费,经历过患者的便利,所花费或节省的专业时间成本以及对健康结果的正面或负面影响。尽管这项研究并未提供相对于标准化的处方时长个性化的明确答案,但现有证据表明,严格支持28天标准期的政策可能需要进行审查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号